Literature DB >> 22207516

Psoriatic arthritis.

Michael Sean Day1, Denis Nam, Susan Goodman, Edwin P Su, Mark Figgie.   

Abstract

Psoriatic arthritis is a chronic inflammatory arthropathy that affects approximately 6% to 48% of patients with psoriasis. Arthritis is not correlated with the extent of skin disease. Classic radiographic findings of the involved joint include erosion, ankylosis, and fluffy periostitis. Site-specific characteristic deformities such as pencil-in-cup deformity of the phalanges also may be present. The disease typically follows a moderate course, but up to 47% of cases develop into destructive arthritis in which the inflammatory process leads to bony erosion and loss of joint architecture. The mainstay of treatment is biologic therapy (eg, tumor necrosis factor-α inhibitors) in conjunction with disease-modifying antirheumatic drugs. Patients with end-stage joint destruction may require surgery to alleviate pain and restore function. Orthopaedic surgeons should be cognizant of the risk factors (eg, increased risk of cardiovascular disease) and potential complications (eg, poor wound healing and increased risk of infection) associated with psoriatic arthritis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22207516     DOI: 10.5435/JAAOS-20-01-028

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  19 in total

1.  Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA.

Authors:  Joseph F Merola; Vivian Herrera; Jacqueline B Palmer
Journal:  Clin Rheumatol       Date:  2018-07-26       Impact factor: 2.980

2.  Rare presentation of bilateral thumb psoriatic arthritis treated with arthrodesis: a case report.

Authors:  Zachary G Tanenbaum; Joseph D Leider; Cooper B Ehlers; Nicholas A Apseloff; James A Ryan; Michael W Kessler
Journal:  AME Case Rep       Date:  2021-04-25

3.  Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE.

Authors:  Maria Antonietta D'Agostino; Georg Schett; Alejandra López-Rdz; Ladislav Šenolt; Katalin Fazekas; Ruben Burgos-Vargas; Jose Maldonado-Cocco; Esperanza Naredo; Philippe Carron; Anne-Marie Duggan; Punit Goyanka; Maarten Boers; Corine Gaillez
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

4.  Complications of primary total hip arthroplasty among patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and primary osteoarthritis.

Authors:  Qiang Lian; Yun Lian; Kangxian Li; Qinfeng Yang; Kunlian Li; Yiqiao Zheng; Haibing Liu; Zhanjun Shi; Jian Wang
Journal:  BMC Musculoskelet Disord       Date:  2022-10-19       Impact factor: 2.562

Review 5.  Altered bone biology in psoriatic arthritis.

Authors:  Homaira Rahimi; Christopher T Ritchlin
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

Review 6.  Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.

Authors:  Matthew Richard Cawson; Stephen Andrew Mitchell; Chris Knight; Henry Wildey; Dean Spurden; Alex Bird; Michelle Elaine Orme
Journal:  BMC Musculoskelet Disord       Date:  2014-01-20       Impact factor: 2.362

7.  Evolutionary biology and anthropology suggest biome reconstitution as a necessary approach toward dealing with immune disorders.

Authors:  William Parker; Jeff Ollerton
Journal:  Evol Med Public Health       Date:  2013-04-19

8.  Immunologic biomarkers for clinical and therapeutic management of psoriasis.

Authors:  P Cordiali-Fei; L Bianchi; C Bonifati; E Trento; M Ruzzetti; F Francesconi; S Bultrini; G D'Agosto; V Bordignon; V Francavilla; A Tripiciano; A Chiricozzi; E Campione; C Cavallotti; A Orlandi; E Berardesca; A Di Carlo; S Chimenti; F Ensoli
Journal:  Mediators Inflamm       Date:  2014-07-20       Impact factor: 4.711

9.  Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.

Authors:  Huabin F Zhang; Geneviève Gauthier; Robert Hiscock; Jeffrey R Curtis
Journal:  Arthritis Res Ther       Date:  2014-08-22       Impact factor: 5.156

10.  Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.

Authors:  Arthur Kavanaugh; Christopher Ritchlin; Proton Rahman; Lluis Puig; Alice B Gottlieb; Shu Li; Yuhua Wang; Lenore Noonan; Carrie Brodmerkel; Michael Song; Alan M Mendelsohn; Iain B McInnes
Journal:  Ann Rheum Dis       Date:  2014-02-19       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.